Published in Genes Cancer on May 01, 2010
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
Towards Engineering Novel PE-Based Immunotoxins by Targeting Them to the Nucleus. Toxins (Basel) (2016) 0.79
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol (2012) 0.78
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs (2012) 0.75
Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Oncotarget (2017) 0.75
IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget (2017) 0.75
A short amino acid sequence able to specify nuclear location. Cell (1984) 21.17
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
The rate of nuclear cytoplasmic protein transport is determined by the casein kinase II site flanking the nuclear localization sequence of the SV40 T-antigen. EMBO J (1991) 3.27
Nuclear targeting signal recognition: a key control point in nuclear transport? Bioessays (2000) 3.17
Nuclear transport kinetics depend on phosphorylation-site-containing sequences flanking the karyophilic signal of the Simian virus 40 T-antigen. EMBO J (1989) 2.40
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem (1990) 2.04
EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res (2005) 2.02
Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion. J Biol Chem (1993) 1.94
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res (1999) 1.84
The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large T-antigen nuclear localization sequence by importin. J Biol Chem (1997) 1.63
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res (1995) 1.50
Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol (2006) 1.45
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med (2000) 1.41
Domain II mutants of Pseudomonas exotoxin deficient in translocation. J Biol Chem (1989) 1.31
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem (1995) 1.30
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol (1998) 1.28
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res (2008) 1.28
SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence. J Biol Chem (1997) 1.27
Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem (1994) 1.26
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med (2007) 1.25
Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem (1997) 1.21
Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res (2005) 1.20
Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. J Cell Biol (1991) 1.18
Infectious enveloped RNA virus antigenic chimeras. Proc Natl Acad Sci U S A (1992) 1.16
Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med (1994) 1.09
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging (2006) 1.04
Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther (2009) 1.04
Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem (2002) 1.04
Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol (2003) 1.00
Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors. J Biol Chem (1999) 0.96
Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab Invest (2001) 0.93
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys (2008) 0.92
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother (2008) 0.83
Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Mol Cell Biol (1991) 0.83
Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res (1992) 0.83
Subcellular phototoxicity of 5-aminolaevulinic acid (ALA). Lasers Surg Med (1998) 0.80
Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation. Biochemistry (1991) 0.80
Critical importance of the triplet lifetime of photosensitizer in photodynamic therapy of tumor. Photochem Photobiol (1989) 0.80
Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines. Int J Radiat Oncol Biol Phys (2005) 0.77
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res (2005) 2.11
EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res (2005) 2.02
Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. Cancer Biol Ther (2011) 1.45
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A (2002) 1.39
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res (2008) 1.28
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther (2007) 1.27
Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res (2005) 1.20
Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res (2008) 1.17
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev (2007) 1.09
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol (2011) 1.06
Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem (2002) 1.04
Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol (2003) 1.00
IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol (2011) 0.93
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol (2014) 0.91
EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol (2012) 0.91
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One (2013) 0.86
Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem (2012) 0.84
Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother (2008) 0.83
Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem (2013) 0.83
Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound (2013) 0.82
Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol (2014) 0.82
Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol (2013) 0.81
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (2013) 0.81
Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin Cancer Res (2009) 0.80
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol (2012) 0.78
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol (2017) 0.77
Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res (2005) 0.76
Ephs and Ephrins in malignant gliomas. Growth Factors (2014) 0.76
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs (2012) 0.75
866 EphA2 Receptor Represents a New Marker and Therapeutic Target in Pediatric Malignancies. Neurosurgery (2005) 0.75